Table 1.
Characteristic | Value (n = 19) |
---|---|
Age, median (range), y | 43 (27 to 56) |
Sex, male/female, No. | 17/2 |
Duration of HIV, median (IQR), y | 5 (2 to 15) |
HIV viral load, median (IQR), copies/mL | <50 (<50 to 2,599) |
CD4 count, median (IQR), cells/mL | 226 (136 to 439) |
History of Kaposi sarcoma, No. (%) | 12 (66) |
KSHV-MCD flare at time of biopsy, No. (%) | 15 (82) |
KSHV viral load, median (IQR), copies/106 PBMCs | 12,227 (1,923 to 369,231) |
Serum human IL-6, median (IQR), pg/mL | 15.9 (11.2 to 45.4)a |
Serum IL-10, median (IQR), pg/mL | 591 (19 to >10,000) |
KSHV-MCD treatment within 30 days of marrow, No. (%) | |
None | 12 (63) |
High-dose zidovudine and valganciclovir | 4 (21) |
Valganciclovir | 2 (11) |
Cytotoxic therapy | 2 (11) |
Rituximab | 1 (5) |
Laboratory parameters, median (IQR) | |
Hemoglobin, g/L | 89 (79 to 103) |
Platelets, ×109/L | 75 (42 to 206) |
White blood cells, ×109/L | 4.7 (2.8 to 6.7) |
Serum immunoglobulins, mg/dL | |
IgG | 2,880 (1,750 to 4,390) |
IgA | 335 (270 to 460) |
IgM | 101 (81 to 148) |
IgE | 393 (114 to 633) |
CRP, mg/Lb | 84.3 (11.2 to 136.7) |
Sodium, mmol/L | 134 (131 to 138) |
Serum albumin, g/L | 23 (20 to 28) |
CRP, C-reactive protein; HIV, human immunodeficiency virus; IL-6, interleukin-6; IL-10, interleukin-10; IQR, interquartile range; KSHV, Kaposi sarcoma herpesvirus; MCD, multicentric Castleman disease; PBMC, peripheral blood mononuclear cell.
Available for 17 patients; normal range for human IL-6 in healthy volunteers is 2.3 ± 1.1 pg/mL.
CRP was assayed using Siemens Dimension Vista platform (Siemens AG, Munich, Germany); from study inception until May 2009, a standard sensitivity assay (sCRP) was used, which was subsequently replaced by a high-sensitivity CRP (hsCRP) assay. Correction of CRP for values obtained before May 2009 was performed using a formula (hsCRP = sCRP/0.93 + 0.56) that was validated by the National Institutes of Health Clinical Center Department of Laboratory Medicine. Normal CRP was less than 3 mg/L.